07-742 phase I/ feasibility study of short term fondaparinux [fondaparinux sodium] (Arixtra) in chemotherapy-pretreated ovarian carcinoma patients at high risk of progression.

Trial Profile

07-742 phase I/ feasibility study of short term fondaparinux [fondaparinux sodium] (Arixtra) in chemotherapy-pretreated ovarian carcinoma patients at high risk of progression.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Oct 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 06 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top